Ultragenyx Financials

RARE Stock  USD 43.40  0.93  2.19%   
Based on the key measurements obtained from Ultragenyx's financial statements, Ultragenyx is not in a good financial situation at this time. It has a very high odds of going through financial crisis in March. At present, Ultragenyx's Other Current Liabilities is projected to increase significantly based on the last few years of reporting. The current year's Total Current Liabilities is expected to grow to about 338.6 M, whereas Retained Earnings are projected to grow to (2.9 B). Key indicators impacting Ultragenyx's financial strength include:
Current ValueLast YearChange From Last Year 10 Year Trend
Debt Equity Ratio0.150.14
Notably Up
Slightly volatile
Current Ratio2.853.0
Notably Down
Slightly volatile
The essential information of the day-to-day investment outlook for Ultragenyx includes many different criteria found on its balance sheet. An individual investor should monitor Ultragenyx's cash flow, debt, and profitability to accurately make informed decisions on whether to invest in Ultragenyx.

Net Income

(518.68 Million)

  

Ultragenyx Earnings Geography

Please note, the presentation of Ultragenyx's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Ultragenyx's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Ultragenyx's management manipulating its earnings.

Ultragenyx Stock Summary

Ultragenyx competes with X4 Pharmaceuticals, Terns Pharmaceuticals, Day One, PDS Biotechnology, and Inozyme Pharma. Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Ultragenyx Pharmaceutical Inc. was incorporated in 2010 and is headquartered in Novato, California. Ultragenyx Pharmaceu operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 1119 people.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
InstrumentUSA Stock View All
ExchangeNASDAQ Exchange
ISINUS90400D1081
CUSIP90400D108
LocationCalifornia; U.S.A
Business Address60 Leveroni Court,
SectorBiotechnology
IndustryHealth Care
BenchmarkDow Jones Industrial
Websitewww.ultragenyx.com
Phone415 483 8800
CurrencyUSD - US Dollar

Ultragenyx Key Financial Ratios

Ultragenyx Key Balance Sheet Accounts

202020212022202320242025 (projected)
Total Assets1.8B1.5B1.5B1.5B1.7B1.8B
Other Current Liab140.9M134.5M192.9M225.7M259.6M272.6M
Other Liab348.7M376.3M387.6M911.9M1.0B1.1B
Net Debt(665.3M)(265.6M)(101.4M)(170.4M)(153.4M)(161.0M)
Retained Earnings(1.6B)(2.1B)(2.8B)(3.4B)(3.0B)(2.9B)
Accounts Payable12.9M17.1M43.3M42.1M48.4M50.9M
Cash713.5M307.6M132.9M213.6M245.6M202.9M
Other Assets3.5M8.8M20.6M16.8M19.4M20.3M
Net Receivables23.1M28.4M40.4M73.4M84.4M88.6M
Other Current Assets57.6M71.7M68.9M47.6M54.8M34.5M
Total Liab605.2M599.8M1.2B1.2B1.4B1.5B
Total Current Assets1.3B856.6M883.9M732.2M842.0M564.7M
Common Stock67K69K70K82K94.3K47.6K
Net Tangible Assets480.4M978.9M758.4M148.0M170.2M161.7M
Capital Surpluse2.1B2.8B3.0B3.1B3.6B2.0B
Inventory13.0M16.2M26.8M34.0M39.1M41.0M
Intangible Assets131.1M130.8M160.1M166.3M191.2M108.7M
Net Invested Capital1.2B922.6M352.5M275.4M247.9M235.5M
Net Working Capital1.1B675.2M622.7M451.7M519.5M667.7M
Capital Stock67K69K70K82K94.3K72.8K

Ultragenyx Key Income Statement Accounts

202020212022202320242025 (projected)
Interest Expense33.3M29.4M43.0M66.0M75.9M79.7M
Operating Income(330.1M)(381.7M)(648.9M)(569.2M)(512.3M)(486.7M)
Ebit(152.1M)(423.6M)(658.7M)(542.5M)(488.2M)(463.8M)
Research Development412.1M497.2M705.8M648.4M745.7M783.0M
Ebitda(139.8M)(410.3M)(640.5M)(516.5M)(464.8M)(441.6M)
Income Before Tax(185.4M)(453.0M)(701.7M)(608.5M)(547.6M)(520.2M)
Net Income(186.6M)(454.0M)(707.4M)(606.6M)(546.0M)(518.7M)
Income Tax Expense1.2M1.0M5.7M(1.8M)(2.1M)(2.0M)
Total Revenue271.0M351.4M363.3M434.2M499.4M524.4M
Gross Profit264.9M335.4M335.0M389.0M447.4M469.8M
Cost Of Revenue6.1M16.0M28.3M45.2M40.7M32.3M
Tax Provision1.2M1.0M5.7M(1.8M)(2.1M)(2.0M)
Net Interest Income(26.3M)(29.4M)(31.9M)(39.3M)(35.4M)(33.6M)
Interest Income7.0M1.9M11.1M26.7M30.7M32.2M

Ultragenyx Key Cash Accounts

202020212022202320242025 (projected)
Change In Cash290.1M(416.7M)(172.0M)81.8M73.6M77.3M
Free Cash Flow(176.1M)(411.8M)(526.6M)(521.6M)(469.4M)(445.9M)
Depreciation12.3M13.2M18.2M26.0M29.9M31.4M
Other Non Cash Items21.5M11.7M119.8M(12.7M)(14.6M)(13.8M)
Capital Expenditures43.9M73.1M146.1M46.8M53.8M30.5M
Net Income(186.6M)(454.0M)(707.4M)(606.6M)(546.0M)(518.7M)
End Period Cash Flow726.3M309.6M137.6M219.4M252.3M205.5M
Change To Inventory(1.3M)(3.1M)(9.7M)(6.9M)(6.2M)(5.9M)
Investments(209.5M)(201.2M)(291.7M)103.4M93.1M97.7M
Change To Netincome83.2M946K235K74.8M86.0M90.3M
Change Receivables(20.1M)9.8M(5.4M)(12.1M)(13.9M)(14.6M)

Ultragenyx Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Ultragenyx's current stock value. Our valuation model uses many indicators to compare Ultragenyx value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Ultragenyx competition to find correlations between indicators driving Ultragenyx's intrinsic value. More Info.
Ultragenyx is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At present, Ultragenyx's Return On Equity is projected to slightly decrease based on the last few years of reporting. Comparative valuation analysis is a catch-all technique that is used if you cannot value Ultragenyx by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.

Ultragenyx Systematic Risk

Ultragenyx's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Ultragenyx volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was thirty with a total number of output elements of thirty-one. The Beta measures systematic risk based on how returns on Ultragenyx correlated with the market. If Beta is less than 0 Ultragenyx generally moves in the opposite direction as compared to the market. If Ultragenyx Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Ultragenyx is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Ultragenyx is generally in the same direction as the market. If Beta > 1 Ultragenyx moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Ultragenyx Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Ultragenyx's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Ultragenyx growth as a starting point in their analysis.

Price Earnings To Growth Ratio

0.3

At present, Ultragenyx's Price Earnings To Growth Ratio is projected to increase slightly based on the last few years of reporting.

Ultragenyx January 30, 2025 Opportunity Range

Along with financial statement analysis, the daily predictive indicators of Ultragenyx help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Ultragenyx. We use our internally-developed statistical techniques to arrive at the intrinsic value of Ultragenyx based on widely used predictive technical indicators. In general, we focus on analyzing Ultragenyx Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Ultragenyx's daily price indicators and compare them against related drivers.

Complementary Tools for Ultragenyx Stock analysis

When running Ultragenyx's price analysis, check to measure Ultragenyx's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ultragenyx is operating at the current time. Most of Ultragenyx's value examination focuses on studying past and present price action to predict the probability of Ultragenyx's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ultragenyx's price. Additionally, you may evaluate how the addition of Ultragenyx to your portfolios can decrease your overall portfolio volatility.
Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.